Organovo Holdings, Inc.'s Presentation at Cantor Fitzgerald Inaugural Healthcare Conference Now Available via Webcast Replay

Corporate Headquarters

11555 Sorrento Valley Road, Suite 100, San Diego, CA 92121
Tel: (858) 224-1000

Find Us On

Organovo Holdings, Inc.'s Presentation at Cantor Fitzgerald Inaugural Healthcare Conference Now Available via Webcast Replay


SAN DIEGO, July 9, 2015 /PRNewswire/ — Organovo Holdings, Inc. (NYSE MKT: ONVO; “Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using 3D bioprinting technology, announced today that the July 8th presentation given by President and CEO Keith Murphy at Cantor Fitzgerald Inaugural Healthcare Conference is now available via a webcast replay for the next 90 days.
To access the webcast, register at: During the playback, the listener can advance the slides manually using the buttons provided at the upper right of the screen.
Organovo’s 3D bioprinting enables the reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body. The company recently announced collaborations with L’Oreal to produce skin tissue for research and toxicity testing; with Merck to print liver and kidney tissues for studies of drug toxicity and with Yale School of Medicine to develop 3-D organ tissues for surgical transplantation research.  Organovo was named one of The World’s Top 10 Most Innovative Companies of 2015 in Health Care by Fast Company.
The Cantor Fitzgerald conference presentation is targeted towards current information regarding the Company.  An overview of Organovo’s 3D bioprinting technology and company background is available via video presentation at the Company’s website:
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo’s 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The company recently launched its initial product of the planned exVive3DTM portfolio offering, a 3D Human Liver Tissue for use in Toxicology and other preclinical drug testing. Additional products are in development, with anticipated release for an exVive3D™ Human Kidney Tissue in the latter half of calendar year 2016. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous other media outlets. Organovo is changing the shape of medical research and practice. Learn more at
Sign up for email updates and connect with us on Twitter (@Organovo).

To view the original version on PR Newswire, visit:

SOURCE Organovo Holdings, Inc.

Organovo Holdings, Inc., Barry Michaels, Chief Financial Officer, 1-858-224-1000 ex. 3,; Gerry Amato, Amato & Partners, LLC,